(Q67705350)

English

Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease

scientific article published on 01 October 1991

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1720655%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1720655%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

total body irradiation

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720655

8 November 2022

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

author name string

A. M. Gianni

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720655

8 November 2022

S. Siena

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720655

8 November 2022

M. Bregni

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720655

8 November 2022

F. Lombardi

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720655

8 November 2022

L. Gandola

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720655

8 November 2022

P. Valagussa

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720655

8 November 2022

G. Bonadonna

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720655

8 November 2022

language of work or name

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1720655

8 November 2022

publication date

1 October 1991

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1720655%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

full work available at URL

http://annonc.oxfordjournals.org/cgi/content/abstract/2/9/645

online access status

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720655

8 November 2022

https://api.elsevier.com/content/article/PII:S0923753420306657?httpAccept=text/xml

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

https://api.elsevier.com/content/article/PII:S0923753420306657?httpAccept=text/plain

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

http://academic.oup.com/annonc/article-pdf/2/9/645/618681/2-9-645.pdf

Portable Document Format

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1720655%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1720655%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

645-653

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1720655%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1720655%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP

1

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience

2

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Can MOPP be replaced in the treatment of advanced Hodgkin's disease?

3

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Prolonged Disease-Free Survival in Hodgkin's Disease with MOPP Reinduction After First Relapse

5

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission

6

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Salvage treatments in Hodgkin's disease

7

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Is there an effective salvage therapy for advanced Hodgkin's disease?

8

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease

9

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.

10

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study

11

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Treatment of refractory and relapsed Hodgkin's disease: intensive chemotherapy and autologous bone marrow or peripheral blood stem cell support

12

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease

16

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

High dose chemo-radiotherapy for sensitive tumors: is sequential better than concurrent drug delivery?

17

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results.

18

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Alternating versus hybrid MOPP-ABVD in Hodgkin’s disease: The Milan experience

19

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma

22

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Recent advances in the chemotherapy of metastatic osteogenic sarcoma

23

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Prospective evaluation of pulmonary function in cancer patients treated with total body irradiation, high-dose melphalan, and autologous hematopoietic stem cell transplantation

25

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

High-dose VP-16-213 monotherapy for refractory germinal malignancies: a phase II study

27

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Hepatic veno-occlusive disease

28

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Early and late complications of bone marrow transplantation.

29

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation

30

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Total lymphoid irradiation, high-dose chemotherapy and autologous bone marrow transplantation for chemotherapy-resistant Hodgkin's disease

31

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Increase in topoisomerase-II-mediated DNA breaks and cytotoxicity of VP16 in human U937 lymphoma cells pretreated with low doses of methotrexate

32

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood

33

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

35

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Identifiers

10.1093/OXFORDJOURNALS.ANNONC.A058043

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1720655%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1720655%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q67705350&oldid=1767052420"